首页> 外文OA文献 >Activity of clinically relevant antimalarial drugs on plasmodium falciparum mature gametocytes in an atp bioluminescence >transmission blocking> assay
【2h】

Activity of clinically relevant antimalarial drugs on plasmodium falciparum mature gametocytes in an atp bioluminescence >transmission blocking> assay

机译:在atp生物发光>透射阻断>检测中临床相关抗疟药对恶性疟原虫成熟配体细胞的活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Current anti-malarial drugs have been selected on the basis of their activity against the symptom-causing asexual blood stage of the parasite. Which of these drugs also target gametocytes, in the sexual stage responsible for disease transmission, remains unknown. Blocking transmission is one of the main strategies in the eradication agenda and requires the identification of new molecules that are active against gametocytes. However, to date, the main limitation for measuring the effect of molecules against mature gametocytes on a large scale is the lack of a standardized and reliable method. Here we provide an efficient method to produce and purify mature gametocytes in vitro. Based on this new procedure, we developed a robust, affordable, and sensitive ATP bioluminescence-based assay. We then assessed the activity of 17 gold-standard anti-malarial drugs on Plasmodium late stage gametocytes. Methods and Findings: Difficulties in producing large amounts of gametocytes have limited progress in the development of malaria transmission blocking assays. We improved the method established by Ifediba and Vanderberg to obtain viable, mature gametocytes en masse, whatever the strain used. We designed an assay to determine the activity of antimalarial drugs based on the intracellular ATP content of purified stage IV-V gametocytes after 48 h of drug exposure in 96/384-well microplates. Measurements of drug activity on asexual stages and cytotoxicity on HepG2 cells were also obtained to estimate the specificity of the active drugs. Conclusions: The work described here represents another significant step towards determination of the activity of new molecules on mature gametocytes of any strain with an automated assay suitable for medium/high-throughput screening. Considering that the biology of the forms involved in the sexual and asexual stages is very different, a screen of our 2 million-compound library may allow us to discover novel anti-malarial drugs to target gametocyte-specific metabolic pathways. © 2012 Lelièvre et al.
机译:背景:目前的抗疟疾药物是根据其对引起该症状的无性寄生虫无性血液阶段的活性而选择的。在负责疾病传播的性阶段,这些药物中的哪一种也靶向配子体,仍然未知。阻断传播是根除议程中的主要策略之一,需要鉴定出对配子细胞有活性的新分子。然而,迄今为止,大规模测量分子对成熟配子细胞的作用的主要限制是缺乏标准化和可靠的方法。在这里,我们提供了一种在体外产生和纯化成熟配子细胞的有效方法。基于此新程序,我们开发了一种功能强大,价格适中且灵敏的ATP生物发光法。然后,我们评估了17种金标准抗疟药对疟原虫晚期配子细胞的活性。方法和发现:产生大量配子细胞的困难限制了疟疾传播阻断试验的发展。我们改进了由Ifediba和Vanderberg建立的方法,以获取可行的,成熟的配子细胞,无论使用何种菌株。我们设计了一种测定方法,用于根据在96/384孔微孔板中暴露48小时后纯化的IV-V期配子阶段细胞的细胞内ATP含量来确定抗疟药的活性。还获得了对无性阶段药物活性的测量以及对HepG2细胞的细胞毒性的测量结果,以评估活性药物的特异性。结论:此处描述的工作代表了通过适用于中/高通量筛选的自动测定法,确定任何菌株的成熟配子细胞上新分子活性的又一个重要步骤。考虑到涉及性和无性阶段形式的生物学差异很大,我们200万个化合物库的筛选可能使我们能够发现针对配子体特异性代谢途径的新型抗疟疾药物。 ©2012Lelièvre等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号